Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Stacy Cline Amin spoke to Law360 about the U.S. Department of Health and Human Services dropping a Trump-era decision that said the Food and Drug Administration (FDA) didn’t have to require premarket review of lab-developed COVID-19 tests.

FDA Scraps Trump-Era Leeway for Lab Test Authorizations

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Stacy Cline Amin spoke to Law360 about the U.S. Department of Health and Human Services dropping a Trump-era decision that said the Food and Drug Administration (FDA) didn’t have to require premarket review of lab-developed COVID-19 tests.“This withdrawal is a long time coming, but you can tell from how thoughtful and thorough the guidance is that it took a long time to develop,” Stacy said. “Looking beyond COVID-19, I anticipate that both FDA and the industry will pivot now to focus on legislation that will provide long-term certainty and clarity to test developers.”Read the <a target="_blank" href="http:https://media2.mofo.com/v3/assets/blt5775cc69c999c255/blt606ec24915d83a51/627321a5b5ad5f2863c5994c/211115-fda-scraps-trump-era-leeway.pdf">full article</a>.